KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
On August 7, 2017, Kindred Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended June 30, 2017 and recent business developments. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release of Kindred Biosciences, Inc. issued on August 7, 2017. |
Kindred Biosciences, Inc. ExhibitEX-99.1 2 a2017q2financialpressrelea.htm PRESS RELEASE Exhibit Exhibit 99.1 Kindred Biosciences Announces Second Quarter 2017 Financial Results San Francisco,…To view the full exhibit click here
About KINDRED BIOSCIENCES, INC. (NASDAQ:KIN)
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
